<DOC>
	<DOCNO>NCT01002040</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness ( immune response ) license H1N12009 influenza vaccine HIV-infected adult . The study enroll 150 adult ( age 20-59 year ) . Participants randomize 2 group receive either one dose two dos license H1N1 vaccine . Study procedures include : medical history , blood sample complete memory aid . Participants involve study related procedure approximately 6 day .</brief_summary>
	<brief_title>Rapid Evaluation Pandemic H1N1 Influenza Vaccine Adults With HIV</brief_title>
	<detailed_description>During first wave H1N12009 pandemic Canada , adult immune deficiency likely die severe infection Canadians . Of 76 death attribute date new virus , 37 % occur person immune system compromise . Adults human immunodeficiency virus ( HIV ) infection constitute significant proportion at-risk population 56,000 affected individual . Most individual retain capacity respond influenza vaccination . The dose regimen pandemic vaccine base limited study general population , leave open question whether HIV-infected person respond satisfactorily recommend dosing . Availability adjuvanted formulation pandemic vaccine may improve responsiveness two dos may require best possible response . Thus would optimal evaluate safety immunogenicity pandemic vaccine among early HIV-infected person receive , inform subsequent vaccination others . The objective study three-fold : 1 . To evaluate safety immunogenicity H1N12009 influenza vaccine convenience sample adult HIV infection . 2 . To compare immune response subject randomize receive either one two dos adjuvanted vaccine identify optimal regimen . 3 . To complete evaluation soon pandemic vaccine become available inform subsequent use vaccine HIV-infected person .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Laboratoryconfirmed HIV Written inform consent Adults 2059 year age Allergies egg , thimerosal gentamicin sulphate Lifethreatening reaction previous Flu vaccine Bleeding disorder Pregnancy Receipt blood blood product past 3 month Chronic illness Previous labconfirmed H1N12009 infection Receipt nonstudy H1N12009 Seasonal Influenza vaccine 2009/10</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>vaccine ,</keyword>
	<keyword>H1N1</keyword>
	<keyword>influenza</keyword>
	<keyword>H1N1 Influenza vaccine</keyword>
	<keyword>Arepanrix</keyword>
	<keyword>Pandemic</keyword>
	<keyword>H1N1 2009 Influenza</keyword>
	<keyword>HIV preventive vaccine</keyword>
</DOC>